The Application of Physiological-Based Pharmacokinetic Modeling to Quantitatively Assess the Impaction of Gut Bacterial Tyrosine Decarboxylases on the Pharmacokinetics of Oral Levodopa

Taipei Medical University Institutional Repository > 藥學院 > 臨床藥物基因體學暨蛋白質體學碩士學位學程 > 博碩士論文 > Item 987654321/63248

請使用永久網址來引用或連結此文件: http://libir.tmu.edu.tw/handle/987654321/63248

題名:	The Application of Physiological-Based Pharmacokinetic Modeling to Quantitatively Assess the Impaction of Gut Bacterial Tyrosine Decarboxylases on the Pharmacokinetics of Oral Levodopa
作者:	MERCADER, XAVIER JOSEPH
貢獻者:	臨床基因體學暨蛋白質體學碩士學位學程謝堅銘
關鍵詞:	Physiologically-Based Pharmacokinetic (PBPK);Tyrosine Decarboxylase;Levodopa;Enzyme Kinetics;Simcyp
日期:	2023-07-12
上傳時間:	2023-12-07 10:27:09 (UTC+8)
摘要:	Parkinson’s Disease (PD) is a neurodegenerative illness affecting the geriatric population. The dopamine loss associated with this disorder results in various motor and non-motor dysfunctions, generating unintended movements that greatly distress the patient’s quality of life. It has long been established that levodopa is peripherally metabolized to dopamine in the gut which arises in a restriction of available dopamine in the brain. Recently, a novel microbial pathway for the metabolism of levodopa through bacterial tyrosine decarboxylase (tyrDC) was discovered. This study aims to quantitatively examine the influence of tyrDC on oral levodopa metabolism through a Physiologically Based Pharmacokinetic (PBPK) modeling. The in vitro metabolism displayed drastic reduction of levodopa and a concentration-dependent formation of dopamine in the presence of tyrDC over the course of 2 hours. The advantage of PBPK modeling is the ability to predict plasma concentrations without the need to undergo ethical considerations and clinical trials. Developed PBPK model went through validation and the prediction errors from the observed data compared to the simulated peak plasma concentration (Cmax) (mg/L) and Area Under the Curve (AUC) (mg*h/L) after single and multiple-dose simulations were all within two-fold. Correspondingly, our model is fit to predict the PK data of levodopa. After the validation, a series of simulations were employed by our PBPK model integrated with enzyme kinetics parameters. The model predicted reduced levels of levodopa which indicates levodopa metabolism by tyrDC in the gut. The values of the PK profiles of levodopa from the predicted were greatly lowered to as much as 50% in comparison with the clinical data. In conclusion, the devised PBPK model for levodopa successfully predicted the influence of the tyrDC in oral levodopa metabolism. However, a verification should be done in the future by comparing these results with in vivo studies on levodopa treated with tyrDC.
描述:	碩士指導教授:謝堅銘委員:卓爾婕委員:韓嘉莉委員:謝堅銘
資料類型:	thesis
顯示於類別:	[臨床藥物基因體學暨蛋白質體學碩士學位學程] 博碩士論文

文件中的檔案:

檔案	描述	大小	格式	瀏覽次數
index.html		0Kb	HTML	77	檢視/開啟

檢視Licence

在TMUIR中所有的資料項目都受到原著作權保護.

TAIR相關文章

資料載入中.....